In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults Antiviral efficacy of molnupiravir vs ritonavir-nirmatrelvir in patients with symptomatic COVID-19 (The Lancet) Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to complications (JAMA) Antibiotic use among hospitalized patients with COVID-19 (OFID) One week of oral Camostat vs placebo in non-hospitalized adults with COVID-19 Assessment of the available therapeutic approaches for severe COVID-19 (Nature) Optimal duration of systemic Corticosteroids in COVID-19 treatment (OFID) Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and in patients with long-COVID syndrome (Nature) Local budesonide therapy in the management of persistent hyposmia in suspected COVID-19 patients (JID) Safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with Kidney disease and COVID-19 Contribute to our Floating Doctors fundraiser at PWB Letters read on TWiV 1052 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv